| Jul 10 |
argenx SE: A Post FDA Approval Assessment
|
| Jun 28 |
Argenx: Strong Setup For Outperformance In 2025
|
| Jun 26 |
Hidden Gems: Three Stocks Estimated Below Market Value in June 2024
|
| Jun 25 |
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
|
| Jun 25 |
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
|
| Jun 24 |
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
| Jun 24 |
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
|
| Jun 24 |
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
|
| Jun 24 |
FDA approves argenx’s VYVGART Hytrulo for CIDP treatment
|
| Jun 21 |
Argenx gets FDA approval for Vyvgart Hytrulo for CIDP (update)
|
